Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)β’ Click on a phase to view related trials
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 85
- Registration Number
- NCT05491525
- Locations
- πΊπΈ
Children's Hospital of Orange County, Orange, California, United States
πΊπΈNemours Childrens Health, Jacksonville, Jacksonville, Florida, United States
πΊπΈWichita Urology Group, Wichita, Kansas, United States
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 403
- Registration Number
- NCT05067478
- Locations
- πΊπΈ
Urology Centers of Alabama, Homewood, Alabama, United States
πΊπΈ43rd Medical Associates, Phoenix, Arizona, United States
πΊπΈFiel Family and Sports Medicine, PC, Tempe, Arizona, United States
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
- Conditions
- Overactive Bladder With Urge Urinary Incontinence
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 80
- Registration Number
- NCT04211831
- Locations
- πΊπΈ
Coastal Clinical Research Inc, Mobile, Alabama, United States
πΊπΈUrological Associates of Southern Arizona, Tucson, Arizona, United States
πΊπΈOrange County Urology Associates, Laguna Hills, California, United States
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 276
- Registration Number
- NCT04103450
- Locations
- πΊπΈ
Private Practice, Las Vegas, Nevada, United States
πΊπΈClinical Trials Research, Lincoln, California, United States
πΊπΈAmerican Institute of Research, Los Angeles, California, United States
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 1105
- Registration Number
- NCT03902080
- Locations
- πΊπΈ
Urology Centers of Alabama, Homewood, Alabama, United States
π¨π¦Private Practice, Brampton, Ontario, Canada
πΊπΈCoastal Clinical Research, Inc., Mobile, Alabama, United States
- Prev
- 1
- 2
- 3
- Next